Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug developer Vertex Pharmaceuticals (Nasdaq: VRTX ) soared a whopping 45% today on news that its cystic fibrosis drug Kalydeco, in combination with its experimental VX-809, led to improved lung function in a mid-stage study.
So what: About 70,000 people live with cystic fibrosis worldwide, so the news naturally triggers excitement over the two-drug therapy's blockbuster prospects. Vertex shares were crushed in late 2012 on signs that competitors were quickly gaining ground in the hepatitis C treatment space, but today's massive surge has the stock back near its 52-week highs.
Now what: Vertex said it would look to begin clinical trials for the combination therapy near the end of 2012 or early 2013. "These data did exceed our expectations," Vertex CEO Jeff Leiden said on a conference call with analysts. "They are leading us to accelerate 809 and Kalydeco into pivotal trials." I'm always leery about buying into a rally as spectacular as this one, but given the therapy's legitimate multibillion-dollar sales potential, multibagger returns from this point aren't out of the realm of possibility.
Interested in more info on Vertex? Add it to your watchlist.